Patheon is expanding its Toronto manufacturing facility, adding 10,000 sq. ft. of GMP space dedicated to the production of oral contraceptives. This includes full-scale commercial production capabilities, including dispensing, granulation, compression, film coating and primary packaging, and has a potential output of 1.3 billion tablets. The new area will use abatement technology, which is used for the elimination of solvent emissions. The dedicated space for oral contraceptive production ful...